Exercise and GLP-1 RA on Insulin Secretion

Sponsor
University of Copenhagen
Study ID
NCT04383197
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Endurance exercise training — BEHAVIORAL
    Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
  • Semaglutide — DRUG
    3 months of therapeutic treatment with semaglutide

Study Details

The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.

Key Dates

Start date
Dec 10, 2019
Status verified
Feb 2021
Primary completion
Aug 31, 2021
Completion
Aug 31, 2022

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide treatment
    3 months of therapeutic semaglutide treatment
  • Experimental: Semaglutide and Endurance exercise
    12 weeks of endurance exercise concomitant to semaglutide treatment
  • Experimental: Endurance exercise
    12 weeks of endurance exercise

Primary Outcome Measure

Insulin secretion [ Time Frame: Change from baseline insulin secretion after Exercise intervention(12 weeks). ]

Central Contacts

Related Studies